Medpace (NASDAQ:MEDP – Get Free Report) and Quanterix (NASDAQ:QTRX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Medpace and Quanterix, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medpace | 0 | 11 | 2 | 0 | 2.15 |
| Quanterix | 1 | 2 | 0 | 0 | 1.67 |
Medpace currently has a consensus price target of $584.18, suggesting a potential upside of 1.23%. Quanterix has a consensus price target of $4.00, suggesting a potential upside of 14.94%. Given Quanterix’s higher probable upside, analysts plainly believe Quanterix is more favorable than Medpace.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medpace | $2.53 billion | 6.37 | $451.12 million | $17.06 | 33.83 |
| Quanterix | $138.90 million | 1.18 | -$107.15 million | ($2.36) | -1.47 |
Medpace has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
78.0% of Medpace shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Comparatively, 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Medpace and Quanterix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medpace | 17.67% | 110.15% | 24.84% |
| Quanterix | -71.86% | -23.92% | -17.66% |
Volatility & Risk
Medpace has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
Summary
Medpace beats Quanterix on 12 of the 14 factors compared between the two stocks.
About Medpace
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.
About Quanterix
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
